Dyne Therapeutics (NASDAQ:DYN) Now Covered by Jones Trading

Jones Trading initiated coverage on shares of Dyne Therapeutics (NASDAQ:DYN) in a research report released on Thursday morning,Benzinga reports. The brokerage issued a buy rating and a $30.00 price objective on the stock.

Other equities analysts also recently issued research reports about the company. Sanford C. Bernstein began coverage on Dyne Therapeutics in a research report on Tuesday. They issued a “market perform” rating and a $13.00 target price on the stock. HC Wainwright lowered their target price on shares of Dyne Therapeutics from $46.00 to $38.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Guggenheim reaffirmed a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a report on Wednesday, June 18th. Robert W. Baird reduced their target price on shares of Dyne Therapeutics from $46.00 to $32.00 and set an “outperform” rating for the company in a research report on Wednesday, June 18th. Finally, Raymond James Financial started coverage on shares of Dyne Therapeutics in a research note on Wednesday, June 11th. They issued an “outperform” rating and a $37.00 price target on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $41.13.

Dyne Therapeutics Stock Down 3.6%

DYN stock opened at $10.05 on Thursday. Dyne Therapeutics has a 52 week low of $6.36 and a 52 week high of $47.45. The firm has a 50-day simple moving average of $11.80 and a 200-day simple moving average of $14.08. The stock has a market capitalization of $1.14 billion, a P/E ratio of -2.80 and a beta of 1.16.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.17). On average, analysts expect that Dyne Therapeutics will post -3.44 earnings per share for the current year.

Hedge Funds Weigh In On Dyne Therapeutics

Hedge funds have recently modified their holdings of the business. Rhumbline Advisers lifted its holdings in shares of Dyne Therapeutics by 4.2% in the 1st quarter. Rhumbline Advisers now owns 133,627 shares of the company’s stock worth $1,398,000 after acquiring an additional 5,383 shares during the last quarter. Optimize Financial Inc purchased a new stake in Dyne Therapeutics in the first quarter valued at approximately $154,000. Exome Asset Management LLC purchased a new stake in Dyne Therapeutics in the first quarter valued at approximately $2,703,000. Caxton Associates LLP acquired a new position in Dyne Therapeutics during the first quarter worth $157,000. Finally, Voleon Capital Management LP purchased a new position in shares of Dyne Therapeutics during the first quarter worth $624,000. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.